Drug Trial Radar · NCT07801820
Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jun 23, 2026
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Shanghai Minwei Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo- and active-controlled, multicenter Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of MWN109 tablets in participants with type 2 diabetes mellitus (T2DM). Eligible participants will be randomized to receive different dose levels of MWN109 tablets, MWN109-matched placebo, or semaglutide tablets 14 mg (active control), administered once daily for 20 consecutive weeks. Approximately 240 adults aged 18 to 75 years with type 2 diabetes mellitus will be enrolled. The primary endpoint is the percent change from baseline in HbA1c at Week 20. Secondary endpoints include glycemic parameters, body weight, metabolic parameters, adverse events, and immunogenicity.
Conditions
- Type 2 Diabetes Mellitus (T2DM)
Interventions
MWN109 1Drug
Administered orally, QD, 20 weeks
MWN109 2Drug
Administered orally, QD, 20 weeks
MWN109 3Drug
Administered orally, QD, 20 weeks
MWN109 4Drug
Administered orally, QD, 20 weeks
PlaceboDrug
Administered orally, QD, 20 weeks
Semaglutide TabletsDrug
Administered orally, QD, 20 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 20 Compared to PlaceboTime frame: Baseline, Week 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.